U.S. stocks were lower, with the Dow Jones falling more than 200 points on Monday.
Shares of Paramount Skydance Corporation (NASDAQ:PSKY) rose sharply during Monday's session after the company launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc (NASDAQ:WBD) for $30 per share, valuing the company at $108.4 billion and including its Global Networks segment.
Paramount said it plans to create a scaled Hollywood leader by combining Paramount and Warner Bros.
Paramount Skydance shares jumped 9.8% to $14.68 on Monday.
Here are some other big stocks recording gains in today’s session.
- Wave Life Sciences Ltd. (NASDAQ:WVE) shares jumped 129.1% to $17.16 after the company reported positive interim Phase 1 data showing its obesity drug WVE-007 delivered GLP-1-like fat loss at three months without muscle loss and was generally safe and well tolerated.
- Structure Therapeutics Inc. (NASDAQ:GPCR) gained 100.5% to $69.30 after the company announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) rose 62.3% to $14.44 after the company reported initial results from the 20 mg dose cohort of its Phase 1b PIONEER trial of Pociredir in sickle cell disease, showing a clear dose-response and robust fetal hemoglobin induction at week 6.
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares gained 51.2% to $100.75 after the company reported its Broaden Phase 1B trial of KT-621 achieved deep STAT6 degradation across dose groups.
- Confluent, Inc. (NASDAQ:CFLT) rose 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share.
- Ocular Therapeutix, Inc. (NASDAQ:OCUL) gained 28.5% to $16.16 after the company announced plans to accelerate its NDA submission timeline for AXPAXLI in Wet AMD. HC Wainwright raised its price target on the stock from $19 to $21.
- Nurix Therapeutics, Inc. (NASDAQ:NRIX) gained 19.6% to $21.64 after the company announced new clinical data from the Company’s ongoing Phase 1a/1b NX-5948-301 study of bexobrutideg in patients with relapsed or refractory B-cell malignancies.
- Cullinan Therapeutics, Inc. (NASDAQ:CGEM) rose 15.6% to $12.25 after the company announced updated clinical data from its Phase 1 study of CLN-049 in patients with r/r AML and MDS, which will be presented at the ASH Annual Meeting and Exposition.
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) jumped 15.3% to $70.86 after the company announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT.
- Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 12.8% to $22.89 after the company said its registrational expansion cohort in the Phase 1/2 DELIVER trial met the primary endpoint for its Duchenne muscular dystrophy therapy.
- Carvana Co. (NYSE:CVNA) gained 11.6% to $446.29 after it was announced the company will join the S&P 500 on December 22, 2025.
- Praxis Precision Medicines, Inc. (NASDAQ:PRAX) jumped 10.2% to $273.31 after multiple analyst firms raised their respective price targets on the stock.
- Arcellx, Inc. (NASDAQ:ACLX) shares rose 8.3% to $75.32 after the company reported that Anito-Cel demonstrated a 96% overall response rate and 74% complete/sCR rate in the iMMagine-1 trial for relapsed/refractory multiple myeloma.
- Flex Ltd. (NASDAQ:FLEX) gained 8.1% to $67.47.
- Primoris Services Corporation (NYSE:PRIM) gained 7.9% to $135.63 after the company was added to the S&P SmallCap 600.
- Warby Parker Inc. (NYSE:WRBY) rose 7.2% to $20.12.
- GitLab Inc. (NASDAQ:GTLB) gained 6.5% to $39.78.
Photo via Shutterstock
